BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nebratamig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nebratamig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06066203-3107@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nebratamig: Phase 1/2 readout est. (NCT06066203)
DESCRIPTION:Nebratamig\, phase 1/2.\nStudy: A Study of GNC-035 in Relapsed 
 or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
 \nEstimated primary completion: December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/nebratamig#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06066203
URL:https://assetmemo.bio/drug/nebratamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
